ArticleJournal of cosmetic dermatology2026
Senomorphic Activity of a Novel Standardized Propolis Extract in Human Dermal Fibroblasts: Molecular Insights Into Clinically Proven Anti-Wrinkle Efficacy.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe recently demonstrated in a randomized controlled trial (RCT) that a Standardized Propolis Extract (SPE), produced via a patented non-alcoholic PEG 400/lecithin process, achieves significant clinical anti-wrinkle efficacy (34% wrinkle depth reduction). The present study investigates the underlying molecular mechanisms, specifically its potential senomorphic activity-the ability to modulate the Senescence-Associated Secretory Phenotype (SASP) without inducing cell death.
objectiveTo evaluate the senomorphic activity of this chemically defined SPE (standardized to 1318.43 μg/g total phenolic markers) in an in vitro model of oxidative stress-induced senescence, providing molecular insights into its clinically observed anti-aging effects.
methodsHuman Dermal Fibroblasts (HDFs) were pre-treated with SPE (0.01%, 0.05%) or Rapamycin (3 μM, reference senomorphic control). Senescence was induced via a validated stress-induced premature senescence (SIPS) protocol (200 μM H
resultsThe 0.05% SPE demonstrated potent senomorphic activity, significantly suppressing the key SASP marker IL-6 (FC: -7.78, p = 0.003)-comparable to the Rapamycin control (FC: -8.1, p = 0.003). Uniquely, SPE induced transcriptional upregulation of CDK4 (FC: +6.71, p = 0.002) and CDKN1A/p21 (FC: +2.33, p = 0.005), effects not observed with Rapamycin. In exploratory MSC experiments, SPE qualitatively reduced SA-β-gal staining.
conclusionThis first-in-class standardized propolis extract demonstrates distinct senomorphic activity, suppressing the inflammatory SASP (IL-6) while inducing transcriptional modulation of pro-regenerative pathways (CDK4). These molecular findings provide mechanistic insights consistent with the extract's clinically proven anti-wrinkle efficacy, supporting its positioning as an evidence-based active ingredient for dermo-cosmetic formulations targeting inflammaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.